In an order posted to the site of the U.S. District Court for the District of Delaware, the court stated: “10x Genomics (TXG), Inc. and Prognosys Biosciences, Inc. sued NanoString Technologies, Inc.1 for patent infringement. Following a five-day trial, the jury found that NanoString willfully, directly, and indirectly infringed 10x’s asserted patents. The jury awarded 10x over twenty-five million dollars in lost profits and over six million dollars in lost royalties. NanoString has moved for judgment as a matter of law on invalidity, infringement, and damages or, in the alternative, for a new trial. 10x, on the other hand, has moved for entry of a permanent injunction, enhancement of damages, attorneys’ fees, supplemental damages, and pre-judgment and post-judgment interest… the Court denies NanoString’s motion and grants 10x’s motion in part.” The filing noted: “Bruker (BRKR) Corporation acquired NanoString following the filing of these motions. In this decision, the Court will refer to the defendants as NanoString.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TXG:
- 10x Genomics price target lowered to $19 from $21 at Barclays
- 10x Genomics’ Visium HD selected by TechBio startup Cure51
- 10X Genomics CEO Serge Saxonov Initiates Rule 10b5-1 Trading Plan Amid Strategic Financial Maneuvering
- 10x Genomics price target lowered to $23 from $35 at Citi
- 10x Genomics Reports Mixed Q3 2024 Results
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
